Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation (IGI) Inc. has signed with Abbvie Inc. a global licensing partnership for trispecific antibody ISB-2001 worth $1.925 billion plus royalties. ISB-2001, which targets BCMA, CD38 and CD3, is in a phase I trial for relapsed/refractory multiple myeloma and has orphan drug and fast track status in the U.S
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Eton, Fujifilm, Humacyte, Immunitybio, Jiangsu Hengrui, Johnson & Johnson, Norgine, Novaliq, Novartis, Zyversa.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adagene, Boston, Cargo, Concentra, Conjugate, Dizlin, GSK, Neuraxpharm, Novartis, Predictive Oncology, Rallybio, Recursion.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biomx, Briacell, Lutris, Nuvectis, Oncolytics, Passage, Prokidney.
New hires and promotions in the biopharma industry, including: Abdera, Agios, Ascentage, Centauri, Crescent, Diagonal, Engene, Feliqs, Hansa, Indivior, Nuevocor.
China has proved to be a fertile ground for innovation as evidenced by some big deals in the antibody-drug conjugate (ADC) space, and the number of candidates entering clinical trials in China or being advanced in the U.S. by Chinese companies.
Under a new licensing deal announced July 8, JCR Pharmaceuticals Co. Ltd. granted Alexion Pharmaceuticals Inc. rights to its adeno-associated virus (AAV) capsids for use in up to five of Alexion’s genomic medicines programs.
Actithera A/S is poised to bring small-molecule pharmacokinetics to radiopharmaceuticals after closing a $75.5 million series A that will fund initial clinical development of a candidate targeting the elusive fibroblast activation protein (FAP).
RSS
